Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 1,097 shares, a growth of 79.8% from the February 12th total of 610 shares. Based on an average daily volume of 1,575 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.7% of the company’s stock are sold short. Currently, 0.7% of the company’s stock are sold short. Based on an average daily volume of 1,575 shares, the days-to-cover ratio is presently 0.7 days.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC purchased a new position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned approximately 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent filing with the Securities & Exchange Commission.

Amplify Weight Loss Drug & Treatment ETF Stock Down 0.5%

Shares of THNR traded down $0.11 during trading on Friday, reaching $24.30. The company’s stock had a trading volume of 297 shares, compared to its average volume of 3,006. The company has a market cap of $3.65 million, a price-to-earnings ratio of 24.31 and a beta of 0.61. The company has a fifty day moving average of $25.90 and a two-hundred day moving average of $24.83. Amplify Weight Loss Drug & Treatment ETF has a twelve month low of $18.56 and a twelve month high of $27.28.

Amplify Weight Loss Drug & Treatment ETF Announces Dividend

The business also recently announced an annual dividend, which was paid on Wednesday, December 31st. Stockholders of record on Tuesday, December 30th were given a $0.4132 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a dividend yield of 162.0%.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.